Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Blackpink's solo journeys: Complementary paths, not competition
-
5
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
6
Korean Air offers special flights for mileage users
-
7
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
8
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
9
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
10
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
Samsung BioLogics Co., a medicine-producing subsidiary of South Korea's Samsung Group, on Thursday won preliminary approval from the nation's bourse for its listing plan.
It allows the firm to start the formal process for the initial public offering estimated to value at around 3 trillion won ($2.7 billion).
Wrapping up more than a month-long review, a related committee of the Korea Exchange concluded that the company is qualified to be listed on the KOSPI market.
The exchange plans to make its final decision on whether to permit the firm's listing after its IPO.
Samsung BioLogics is a contract manufacturer of biologic drugs, made from living cells, for global pharmaceutical firms. It is 52.1 percent owned by Samsung Group's de-facto holding company Samsung C&T Corp. and 47.8 percent controlled by Samsung Electronics Co., a global tech giant.
Samsung BioLogics owns 91.2 percent of Samsung Bioepis Co., which develops copies of biotech drugs that are often called biosimilars.
It posted 1.9 trillion won in net profit in 2015, according to its separate financial statement. (Yonhap)
It allows the firm to start the formal process for the initial public offering estimated to value at around 3 trillion won ($2.7 billion).
Wrapping up more than a month-long review, a related committee of the Korea Exchange concluded that the company is qualified to be listed on the KOSPI market.
The exchange plans to make its final decision on whether to permit the firm's listing after its IPO.
Samsung BioLogics is a contract manufacturer of biologic drugs, made from living cells, for global pharmaceutical firms. It is 52.1 percent owned by Samsung Group's de-facto holding company Samsung C&T Corp. and 47.8 percent controlled by Samsung Electronics Co., a global tech giant.
Samsung BioLogics owns 91.2 percent of Samsung Bioepis Co., which develops copies of biotech drugs that are often called biosimilars.
It posted 1.9 trillion won in net profit in 2015, according to its separate financial statement. (Yonhap)
